Navigation Links
Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
Date:11/16/2009

NEW YORK, Nov. 16 /PRNewswire/ -- Personalized Pharmaceutical Systems (PPS) today announced the sale of the Angioedema Clinical Prediction Guide to Viropharma Incorporated.

PPS is a clinical trial enrichment and market differentiation company which has developed advanced technology in phenomics to help drug companies identify the correct patients for their drugs, and as a result help patients get the right drug the first time. Through the use of its phenomic technology, PPS developed the Angioedema Clinical Prediction Guide to help emergency room physicians quickly differentiate amongst different types of angioedema (AE) that can be life-threatening.

Allergic angioedema is more common, and can be treated with antihistaminergic treatments. Hereditary Angioedema (HAE) is a rare form of AE seen in less than 1% of AE patients presenting to emergency rooms, and is not treatable with antihistaminergic treatments. Due to both the rareness of HAE and the complexity of differentiating amongst the various types of AE, the HAE patient is often misdiagnosed and treated inappropriately in the emergency room, increasing the risk of life-threatening airway compromise.

Correct diagnosis of HAE is known to take, on average, several years from a patient's first visit to an emergency room. Viropharma has licensed the Angioedema Clinical Prediction Guide and is currently considering a large-scale retrospective validation analysis. If validated, Viropharma may use the Angioedema Clinical Prediction Guide as a component of their medical education strategy to give physicians a means to recognize rarer forms of AE, and thereby accelerate the referral and diagnosis of HAE.

"We are extremely pleased with this opportunity for Viropharma to use our technology to accelerate the diagnosis of patients with this very severe disease. We look forward to the possibility of future collaboration and new opportunities to optimize Viropharma's clinical trial design, increase physician awareness, and maximize patient access," Dr. Paul Herscu, CEO, PPS.

About Personalized Pharmaceutical Systems LLC

Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enhancement and market differentiation company designed to dramatically reduce risk for pharmaceutical companies in both drug development and post-market entry phases. PPS novel enrichment technology utilizes inter-individual variability, that currently confounds drug trials, to enhance efficacy outcomes and/or significantly reduce risk of adverse effects. PPS technology effectively dissects diagnostic populations into treatment response correlated subgroups through the analysis of thousands of clinical indices measured against a continuum of environmental variables. While most clinical trials currently compare 40-50 clinical indices against clinical outcomes, PPS templates consider over 1000 indices mapped against a continuum of environmental variations and tested in thousands of patients over the past 15 years. This level of granularity brings a new level of precision to provide reliable determination of true clinical phenotype at the whole patient level. This technology creates new opportunity for success with compounds that are stalled or failing in current trials. PPS technology can be seamlessly incorporated into existing Phase II-IV trials.

SOURCE Personalized Pharmaceutical Systems


'/>"/>
SOURCE Personalized Pharmaceutical Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
4. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
5. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
6. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
7. Personalized Medicine Expert: Dont Fix It, Predict It
8. Personalized Medicine Killer Apps Will Transform Care Model
9. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
10. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
11. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):